JUPITER: a few words of caution.
作者信息
Vaccarino Viola, Bremner J Douglas, Kelley Mary E
机构信息
Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA 30306, USA.
出版信息
Circ Cardiovasc Qual Outcomes. 2009 May;2(3):286-8. doi: 10.1161/CIRCOUTCOMES.109.850404.
Abstract
摘要
相似文献
1
JUPITER: a few words of caution.JUPITER：几点注意事项。
Circ Cardiovasc Qual Outcomes. 2009 May;2(3):286-8. doi: 10.1161/CIRCOUTCOMES.109.850404.
2
The JUPITER trial: results, controversies, and implications for prevention.JUPITER试验：结果、争议及预防意义
Circ Cardiovasc Qual Outcomes. 2009 May;2(3):279-85. doi: 10.1161/CIRCOUTCOMES.109.868299.
3
The stain wars.染色之争。
Lancet. 2003 Nov 29;362(9398):1855-6; discussion 1856. doi: 10.1016/s0140-6736(03)14934-3.
4
Effect of rosuvastatin on fatigue in patients with heart failure.
J Am Coll Cardiol. 2013 Mar 12;61(10):1121-2. doi: 10.1016/j.jacc.2012.12.004.
5
Rosuvastatin in patients with elevated C-reactive protein.
N Engl J Med. 2009 Mar 5;360(10):1038-9; author reply 1041-2.
6
Should rosuvastatin be withdrawn from the market?
Lancet. 2004;364(9445):1579; discussion 1579-80. doi: 10.1016/S0140-6736(04)17304-2.
7
Rosuvastatin (Crestor) and rhabdomyolysis.瑞舒伐他汀（可定）与横纹肌溶解症
CMAJ. 2004 Jul 20;171(2):129. doi: 10.1503/cmaj.1041051.
8
New analysis supports expanded use of statins in women.新的分析支持扩大他汀类药物在女性中的使用。
Harv Womens Health Watch. 2010 Apr;17(8):6.
9
Successful desensitization to rosuvastatin in a patient with a history of anaphylaxis to multiple statins.一名对多种他汀类药物有过敏反应病史的患者成功实现瑞舒伐他汀脱敏。
J Allergy Clin Immunol. 2013 Jan;131(1):234-6. doi: 10.1016/j.jaci.2012.10.009. Epub 2012 Nov 21.
10
Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes.瑞舒伐他汀强化降脂治疗在合并2型糖尿病的高胆固醇血症患者中的有效性
Endocrine. 2009 Dec;36(3):412-8. doi: 10.1007/s12020-009-9235-6. Epub 2009 Oct 16.
引用本文的文献
1
Anti-Inflammatory Therapy in Coronary Artery Disease: Where Do We Stand?冠状动脉疾病中的抗炎治疗：我们目前的状况如何？
Rev Cardiovasc Med. 2023 Jan 4;24(1):10. doi: 10.31083/j.rcm2401010. eCollection 2023 Jan.
2
Historical Review of the Use of Relative Risk Statistics in the Portrayal of the Purported Hazards of High LDL Cholesterol and the Benefits of Lipid-Lowering Therapy.关于使用相对风险统计数据描述高LDL胆固醇的所谓危害及降脂治疗益处的历史回顾。
Cureus. 2023 May 1;15(5):e38391. doi: 10.7759/cureus.38391. eCollection 2023 May.
3
Long non-coding RNA ANRIL in gene regulation and its duality in atherosclerosis.长链非编码RNA ANRIL在基因调控中的作用及其在动脉粥样硬化中的双重性
J Huazhong Univ Sci Technolog Med Sci. 2017 Dec;37(6):816-822. doi: 10.1007/s11596-017-1812-y. Epub 2017 Dec 21.
4
Biomarkers: hopes and challenges in the path from discovery to clinical practice.生物标志物：从发现到临床实践的道路上的希望与挑战。
Transl Res. 2012 Apr;159(4):197-204. doi: 10.1016/j.trsl.2012.01.023. Epub 2012 Feb 14.
5
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.瑞舒伐他汀、炎症、C反应蛋白、JUPITER研究与心血管疾病的一级预防——一种观点
Drug Des Devel Ther. 2010 Dec 9;4:383-413. doi: 10.2147/DDDT.S10812.
本文引用的文献
1
From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey.从这里到“朱庇特”：利用1999 - 2004年国家健康与营养检查调查的数据识别他汀类药物治疗的新患者
Circ Cardiovasc Qual Outcomes. 2009 Jan;2(1):41-8. doi: 10.1161/CIRCOUTCOMES.108.832592. Epub 2009 Jan 13.
2
The Neurontin legacy--marketing through misinformation and manipulation.加巴喷丁的遗留问题——通过错误信息和操纵手段进行营销。
N Engl J Med. 2009 Jan 8;360(2):103-6. doi: 10.1056/NEJMp0808659.
3
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.瑞舒伐他汀预防C反应蛋白升高的男性和女性发生血管事件。
N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.
4
Expanding the orbit of primary prevention--moving beyond JUPITER.扩大一级预防的范围——超越《朱庇特研究》
N Engl J Med. 2008 Nov 20;359(21):2280-2. doi: 10.1056/NEJMe0808320. Epub 2008 Nov 9.
5
Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions.与由非营利组织支持或无支持的荟萃分析相比，行业支持的荟萃分析：方法学质量和结论的差异。
BMC Med Res Methodol. 2008 Sep 9;8:60. doi: 10.1186/1471-2288-8-60.
6
Early stopping of randomized clinical trials for overt efficacy is problematic.因明显疗效而提前终止随机临床试验存在问题。
J Clin Epidemiol. 2008 Mar;61(3):241-6. doi: 10.1016/j.jclinepi.2007.07.016.
7
Ethical issues in stopping randomized trials early because of apparent benefit.因明显获益而提前终止随机试验中的伦理问题。
Ann Intern Med. 2007 Jun 19;146(12):878-81. doi: 10.7326/0003-4819-146-12-200706190-00009.
8
Randomized trials stopped early for benefit: a systematic review.因有益而提前终止的随机试验：一项系统评价
JAMA. 2005 Nov 2;294(17):2203-9. doi: 10.1001/jama.294.17.2203.
9
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.降低胆固醇治疗的疗效与安全性：对他汀类药物14项随机试验中90,056名参与者数据的前瞻性荟萃分析
Lancet. 2005 Oct 8;366(9493):1267-78. doi: 10.1016/S0140-6736(05)67394-1. Epub 2005 Sep 27.
10
Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association.预防癌症、心血管疾病和糖尿病：美国癌症协会、美国糖尿病协会和美国心脏协会的共同议程。
Diabetes Care. 2004 Jul;27(7):1812-24. doi: 10.2337/diacare.27.7.1812.
Zotero 插件